Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
topic_facet:"Medical Condition: Type 2 diabetes patients receiving current standard therapy for diabetic nephropathy (ACEi or ARB) with micro- or macroalbuminuria (UACR between 30 and 3000 mg/g creatinine). [ACEi=Angiotensin Converting Enzyme inhibitor; ARB=Angiotensin Receptor Blocker; UACR= Urinary Albumin Creatinine Ratio] MedDRA version: 14.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Type+2+diabetes+patients+receiving+current+standard+therapy+for+diabetic+nephropathy+%28ACEi+or+ARB%29+with+micro-+or+macroalbuminuria+%28UACR+between+30+and+3000+mg%2Fg+creatinine%29.+%5BACEi%3DAngiotensin+Converting+Enzyme+inhibitor%3B+ARB%3DAngiotensin+Receptor+Blocker%3B+UACR%3D+Urinary+Albumin+Creatinine+Ratio%5D+MedDRA+version%3A+14.1Level%3A+SOCClassification+code+10027433Term%3A+Metabolism+and+nutrition+disordersSystem+Organ+Class%3A+10027433+-+Metabolism+and+nutrition+disorders%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Nutritional+and+Metabolic+Diseases+%5BC18%5D%22&lookfor=%22Enzyme+Inhibitors%22&type=Subject
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Type+2+diabetes+patients+receiving+current+standard+therapy+for+diabetic+nephropathy+%28ACEi+or+ARB%29+with+micro-+or+macroalbuminuria+%28UACR+between+30+and+3000+mg%2Fg+creatinine%29.+%5BACEi%3DAngiotensin+Converting+Enzyme+inhibitor%3B+ARB%3DAngiotensin+Receptor+Blocker%3B+UACR%3D+Urinary+Albumin+Creatinine+Ratio%5D+MedDRA+version%3A+14.1Level%3A+SOCClassification+code+10027433Term%3A+Metabolism+and+nutrition+disordersSystem+Organ+Class%3A+10027433+-+Metabolism+and+nutrition+disorders%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Nutritional+and+Metabolic+Diseases+%5BC18%5D%22&lookfor=%22Enzyme+Inhibitors%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Type+2+diabetes+patients+receiving+current+standard+therapy+for+diabetic+nephropathy+%28ACEi+or+ARB%29+with+micro-+or+macroalbuminuria+%28UACR+between+30+and+3000+mg%2Fg+creatinine%29.+%5BACEi%3DAngiotensin+Converting+Enzyme+inhibitor%3B+ARB%3DAngiotensin+Receptor+Blocker%3B+UACR%3D+Urinary+Albumin+Creatinine+Ratio%5D+MedDRA+version%3A+14.1Level%3A+SOCClassification+code+10027433Term%3A+Metabolism+and+nutrition+disordersSystem+Organ+Class%3A+10027433+-+Metabolism+and+nutrition+disorders%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Nutritional+and+Metabolic+Diseases+%5BC18%5D%22&lookfor=%22Enzyme+Inhibitors%22&type=Subject
PubPharm (2)
1
Efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin : A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 mg for 24 weeks in type 2 diabetes patients, with micro- or macroalbuminuria (30-3000mg/g creatinine) on top of current standard treatment for diabetic nephropathy (Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker) ? MARLINA (Efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin) - MARLINA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2016
Wird geladen...
2
Efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin : A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 mg for 24 weeks in type 2 diabetes patients, with micro- or macroalbuminuria (30-3000mg/g creatinine) on top of current standard treatment for diabetic nephropathy (Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker) ? MARLINA (Efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin) - MARLINA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2016
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Medical Condition: Type 2 diabetes patients receiving current standard therapy for diabetic nephropathy (ACEi or ARB) with micro- or macroalbuminuria (UACR between 30 and 3000 mg/g creatinine). [ACEi=Angiotensin Converting Enzyme inhibitor; ARB=Angiotensin Receptor Blocker; UACR= Urinary Albumin Creatinine Ratio] MedDRA version: 14.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Medienart
2
Aufsätze
2
E-Artikel
2
E-Ressourcen
Zeitschriftentitel
2
WHO International Clinical Trials Registry Plat...
Thema
2
610
Medical Condition: Type 2 diabetes patients rec...
2
Phase: Phase 3
2
Recruitment Status: Not yet recruiting
2
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
Erscheinungsjahr(e)
Von:
Bis:
Sprache
2
Englisch
Haven't found what you're looking for?
Wird geladen...